¹⁸F-FET PET for planning of thermotherapy using magnetic nanoparticles in recurrent glioblastoma

References

• Jordan A, Scholz R, Wust P, Fahling H, Krause J, Wlodarczyk W, Sander B, Vogl T, Felix R. Effects of magnetic fluid hyperthermia (MFH) on C3H mammary carcinoma in vivo. Int J Hyperthermia 1997; 13: 587–605
   PubMed Web of Science ®Google Scholar
• Jordan A, Wust P, Scholz R, Tesche B, Fahling H, Mitrovics T, Vogl T, Cervos-Navarro J, Felix R. Cellular uptake of magnetic fluid particles and their effects on human adenocarcinoma cells exposed to AC magnetic fields in vitro. Int J Hyperthermia 1996; 12: 705–722
   PubMed Web of Science ®Google Scholar
• Gneveckow U, Jordan A, Scholz R, Bruess V, Waldoefner N, Ricke J, Feussner A, Hildebrandt B, Rau B, Wust P. Description and characterization of the novel hyperthermia- and thermoablation-system MFH 300F for clinical magnetic fluid hyperthermia. Med Phys 2004; 31: 1444–1451
   PubMed Web of Science ®Google Scholar
• Jordan A, Scholz R, Maier-Hauff K, van Landeghem FK, Waldoefner N, Teichgraeber U, Pinkernelle J, Bruhn H, Neumann F, Thiesen B, von Deimling A, Felix R. The effect of thermotherapy using magnetic nanoparticles on rat malignant glioma. J Neurooncol 2005; 29: 1–8
   Google Scholar
• Johannsen M, Jordan A, Scholz R, Koch M, Lein M, Deger S, Roigas J, Jung K, Loening S. Evaluation of magnetic fluid hyperthermia in a standard rat model of prostate cancer. J Endourol 2004; 18: 495–500
   PubMed Web of Science ®Google Scholar
• Johannsen M, Thiesen B, Jordan A, Taymoorian K, Gneveckow U, Waldoefner N, Scholz R, Koch M, Lein M, Jung K, Loening SA. Magnetic fluid hyperthermia (MFH) reduces prostate cancer growth in the orthotopic Dunning R3327 rat model. Prostate 2005; 64: 283–292
   PubMed Web of Science ®Google Scholar
• Johannsen M, Thiesen B, Gneveckow U, Taymoorian K, Waldoefner N, Scholz R, Deger S, Jung K, Loening SA, Jordan A. Thermotherapy using magnetic nanoparticles combined with external radiation in an orthotopic rat model of prostate cancer. Prostate 2006; 66: 97–104
   PubMed Web of Science ®Google Scholar
• Johannsen M, Gneveckow U, Eckelt L, Feussner A, Waldoefner N, Scholz R, Deger S, Wust P, Loening SA, Jordan A. Clinical hyperthermia of prostate cancer using magnetic nanoparticles: Presentation of a new interstitial technique. Int J Hyperthermia 2005; 21: 637–647
   PubMed Web of Science ®Google Scholar
• Leeds NE, Jackson EF. Current imaging techniques for the evaluation of brain neoplasms. Curr Opin Oncol 1994; 6: 254–261
   PubMedGoogle Scholar
• Kelly PJ, Daumas-Duport C, Scheithauer BW, Kall BA, Kispert DB. Stereotactic histologic correlations of computed tomography- and magnetic resonance imaging-defined abnormalities in patients with glial neoplasms. Mayo Clin Proc 1987; 62: 450–459
   PubMedGoogle Scholar
• Samnick S, Bader JB, Hellwig D, Moringlane JR, Alexander C, Romeike BF, Feiden W, Kirsch CM. Clinical value of iodine-alpha-methyl-]L-thyrosine single-photon emission tomography in the differential diagnosis of recurrent brain tumor in patients pretreated for glioma at follow-up. J Clin Oncol 2002; 20: 396–404
   PubMedGoogle Scholar
• Kuwert T, Woesler B, Morgenroth C, Lerch H, Schafers M, Palkovic S, Matheja P, Brandau W, Wassmann H, Schober O. Diagnosis of recurrent glioma with SPECT and iodine-123-alpha-methyl tyrosine. J Nucl Med 1998; 39: 23–27
   PubMedGoogle Scholar
• Plotkin M, Eisenacher J, Bruhn H, Wurm R, Michel R, Stockhammer F, Feußner A, Dudeck O, Wust P, Felix R, Amthauer H. 123I-IMT SPECT and 1H MR-spectroscopy at 3.0 Tesla in the differential diagnosis of recurrent or residual gliomas: A comparative study. J Neuro Oncol 2004; 70: 49–58
   PubMedGoogle Scholar
• Plotkin M, Amthauer H, Eisenacher J, Wurm R, Michel R, Wust R, Stockhammer F, Gutberlet M, Röttgen R, Ruf J, Felix R. Value of 123I-IMT SPECT for diagnosis of recurrent non-astrocytic intracranial tumours. Neuroradiology 2005; 47: 18–26
   PubMedGoogle Scholar
• Amthauer H, Wurm R, Kuczer D, Ruf J, Michel R, Eisenacher J, Stockhammer F, Denecke T, Felix R, Plotkin M. Relevance of image fusion with MRI for the interpretation of 123I-IMT scans in patients with suspected recurrent or residual brain tumors. Clin Nucl Med 2006; 31: 189–192
   PubMedGoogle Scholar
• Popperl G, Gotz G, Rachinger W, Gildehaus FJ, Tonn JC, Tatsch K. Value of O-(2-[18F]fuoroethyl)-]L-tyrosine PET for the diagnosis of recurrent glioma. Eur J Nucl Med Mol Imag 2004; 11: 1464–1470
   Google Scholar
• Grosu AL, Feldmann H, Dick S, Dzewas B, Nieder C, Gumprecht H, Frank A, Schwaiger M, Molls M, Weber WA. Implications of IMT-SPECT for postoperative radiotherapy planning in patients with gliomas. Int J Radiat Oncol Biol Phys 2002; 54: 842–854
   PubMedGoogle Scholar
• Grosu AL, Weber WA, Riedel E, Jeremic B, Nieder C, Franz M, Gumprecht H, Jaeger R, Schwaiger M, Molls M. ]L-(methyl-11C) methionine positron emission tomography for target delineation in resected high-grade gliomas before radiotherapy. Int J Radiat Oncol Biol Phys 2005; 63: 64–74
   PubMed Web of Science ®Google Scholar
• Nuutinen J, Sonninen P, Lehikoinen P, Sutinen E, Valavaara R, Eronen E, Norrgard S, Kulmala J, Teras M, Minn H. Radiotherapy treatment planning and long-term follow-up with [(11)C] methionine PET in patients with low-grade astrocytoma. Int J Radiat Oncol Biol Phys 2000; 48: 43–52
   PubMed Web of Science ®Google Scholar
• Grosu AL, Weber WA, Franz M, Stark S, Piert M, Thamm R, Gumprecht H, Schwaiger M, Molls M, Nieder C. Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy. Int J Radiat Oncol Biol Phys 2005; 63: 511–519
   PubMed Web of Science ®Google Scholar
• Kracht LW, Miletic H, Busch S, Jacobs AH, Voges J, Hoevels M, Klein JC, Herholz K, Heiss WD. Delineation of brain tumor extent with [11C]L-methionine positron emission tomography: Local comparison with stereotactic histopathology. Clin Cancer Res 2004; 10: 7163–7170
   PubMed Web of Science ®Google Scholar
• Pauleit D, Floeth F, Hamacher K, Riemenschneider MJ, Reifenberger G, Muller HW, Zilles K, Coenen HH, Langen KJ. O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas. Brain 2005; 128: 678–687
   PubMed Web of Science ®Google Scholar
• Weber W, Wester HJ, Grosu AL, Herz M, Dzewas B, Feldmann HJ, Molls M, Stocklin G, Schwaiger M. O-(2-[18F] fluoroethyl)-L-tyrosine and L-[methyl-11C] methionine uptake in brain tumours: Initial results of a comparative study. Eur J Nucl Med 2000; 27: 542–549
   PubMedGoogle Scholar
• Pauleit D, Floeth F, Tellmann L, Hamacher H, Hautzel H, Müller HW, Coenen HH, Langen KJ. Comparison of O-(2-18F-fluoroethyl)-L-tyrosinePET and 3-123I-iodo-α-methyl-L-tyrosine SPECT in brain tumors. J Nucl Med 2004; 45: 374–381
   PubMedGoogle Scholar